[Renal cell carcinoma].
Although medical treatment for advanced renal cell carcinoma has included cytokine therapies such as interferon and interleukin-2, the treatment system has been revolutionized with the emergence of molecular target medicine. A vascular endothelial growth factor and its receptor for the target molecule are the mainstream, but the efficacy of inhibitors of an alternate pathway has been established. It seems that even newer molecular target medicine will be introduced in the future, but the optimal medicine based on the individual condition must be provided in renal cell carcinoma cases.
Obara
Wataru
W
Dept. of Urology, Iwate Medical University School of Medicine, Morioka, Japan.
Fujioka
Tomoaki
T
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007167:Immunotherapy; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000068258:Bevacizumab; C401859:temsirolimus; D000077157:Sorafenib; D000077210:Sunitinib; D020123:Sirolimus